IN8BIO INC (INAB) Stock Fundamental Analysis

NASDAQ:INAB • US45674E2081

1.74 USD
+0.03 (+1.75%)
Last: Feb 27, 2026, 04:10 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to INAB. INAB was compared to 521 industry peers in the Biotechnology industry. INAB may be in some trouble as it scores bad on both profitability and health. INAB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year INAB has reported negative net income.
  • In the past year INAB has reported a negative cash flow from operations.
  • INAB had negative earnings in each of the past 5 years.
  • In the past 5 years INAB always reported negative operating cash flow.
INAB Yearly Net Income VS EBIT VS OCF VS FCFINAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • With a Return On Assets value of -123.20%, INAB is not doing good in the industry: 79.46% of the companies in the same industry are doing better.
  • INAB has a Return On Equity of -156.63%. This is in the lower half of the industry: INAB underperforms 64.88% of its industry peers.
Industry RankSector Rank
ROA -123.2%
ROE -156.63%
ROIC N/A
ROA(3y)-106.89%
ROA(5y)-80.96%
ROE(3y)-152.01%
ROE(5y)-110.17%
ROIC(3y)N/A
ROIC(5y)N/A
INAB Yearly ROA, ROE, ROICINAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K 1.5K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for INAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INAB Yearly Profit, Operating, Gross MarginsINAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • INAB has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, INAB has more shares outstanding
  • Compared to 1 year ago, INAB has a worse debt to assets ratio.
INAB Yearly Shares OutstandingINAB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
INAB Yearly Total Debt VS Total AssetsINAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -11.99, we must say that INAB is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -11.99, INAB is not doing good in the industry: 76.39% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 0.00 indicates that INAB is not too dependend on debt financing.
  • The Debt to Equity ratio of INAB (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.99
ROIC/WACCN/A
WACCN/A
INAB Yearly LT Debt VS Equity VS FCFINAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

  • A Current Ratio of 6.91 indicates that INAB has no problem at all paying its short term obligations.
  • INAB's Current ratio of 6.91 is fine compared to the rest of the industry. INAB outperforms 69.29% of its industry peers.
  • A Quick Ratio of 6.91 indicates that INAB has no problem at all paying its short term obligations.
  • INAB has a Quick ratio of 6.91. This is in the better half of the industry: INAB outperforms 69.48% of its industry peers.
Industry RankSector Rank
Current Ratio 6.91
Quick Ratio 6.91
INAB Yearly Current Assets VS Current LiabilitesINAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 76.04% over the past year.
EPS 1Y (TTM)76.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, INAB will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.77% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y73.62%
EPS Next 2Y37.55%
EPS Next 3Y23.37%
EPS Next 5Y13.77%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INAB Yearly Revenue VS EstimatesINAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M
INAB Yearly EPS VS EstimatesINAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for INAB. In the last year negative earnings were reported.
  • Also next year INAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INAB Price Earnings VS Forward Price EarningsINAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INAB Per share dataINAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

  • INAB's earnings are expected to grow with 23.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.55%
EPS Next 3Y23.37%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for INAB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IN8BIO INC

NASDAQ:INAB (2/27/2026, 4:10:04 PM)

1.74

+0.03 (+1.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-02
Inst Owners19.41%
Inst Owner Change187.65%
Ins Owners6.56%
Ins Owner Change32.74%
Market Cap17.00M
Revenue(TTM)N/A
Net Income(TTM)-20.66M
Analysts82
Price Target50.24 (2787.36%)
Short Float %3.51%
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.36%
Min EPS beat(2)32.25%
Max EPS beat(2)32.46%
EPS beat(4)3
Avg EPS beat(4)27.37%
Min EPS beat(4)-2.94%
Max EPS beat(4)47.71%
EPS beat(8)4
Avg EPS beat(8)7.74%
EPS beat(12)7
Avg EPS beat(12)5.45%
EPS beat(16)9
Avg EPS beat(16)2.97%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-20.13%
EPS NQ rev (3m)32.97%
EPS NY rev (1m)0%
EPS NY rev (3m)10.66%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.29
P/tB 1.29
EV/EBITDA N/A
EPS(TTM)-5.39
EYN/A
EPS(NY)-1.88
Fwd EYN/A
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.49
OCFYN/A
SpS0
BVpS1.35
TBVpS1.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -123.2%
ROE -156.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-106.89%
ROA(5y)-80.96%
ROE(3y)-152.01%
ROE(5y)-110.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.56%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.91
Quick Ratio 6.91
Altman-Z -11.99
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)217.04%
Cap/Depr(5y)140.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.11%
EPS Next Y73.62%
EPS Next 2Y37.55%
EPS Next 3Y23.37%
EPS Next 5Y13.77%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.28%
EBIT Next 3Y-17.46%
EBIT Next 5Y-5.55%
FCF growth 1Y48.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.78%
OCF growth 3YN/A
OCF growth 5YN/A

IN8BIO INC / INAB FAQ

What is the ChartMill fundamental rating of IN8BIO INC (INAB) stock?

ChartMill assigns a fundamental rating of 1 / 10 to INAB.


Can you provide the valuation status for IN8BIO INC?

ChartMill assigns a valuation rating of 1 / 10 to IN8BIO INC (INAB). This can be considered as Overvalued.


What is the profitability of INAB stock?

IN8BIO INC (INAB) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for INAB stock?

The Earnings per Share (EPS) of IN8BIO INC (INAB) is expected to grow by 73.62% in the next year.